AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture

AAOS: Supplement Use Low in Patients With Osteoporosis, Hip Fracture FRIDAY, March 15, 2019 -- Of patients diagnosed with osteoporosis who have a history of hip fracture, only 14 percent are receiving appropriate calcium and vitamin D supplementation, ac

FDA Approves a New Generic Diovan (valsartan)

FDA Approves a New Generic Diovan (valsartan) March 12, 2019 -- Today, the U.S. Food and Drug Administration approved a new generic of Diovan(valsartan). Valsartan is an angiotensin II receptor blocker (ARB) that treats high blood pressure and heart fail

FDA Approves Rocklatan FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension

FDA Approves Rocklatan FDA Approves Rocklatan (netarsudil and latanoprost ophthalmic solution) for the Reduction of Intraocular Pressure in Open-Angle Glaucoma or Ocular Hypertension DURHAM, N.C.--(BUSINESS WIRE)--Mar. 12, 2019-- Aerie Pharmaceuticals

Health Tip: Energy Drink Safety

-- While energy drinks are promoted as products that increase energy and enhance performance, they also can put users at risk. From 2007 to 2011, energy-drink related emergency room visits doubled. Overconsumption of energy drinks can cause a host of i

FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression

FDA Approves Spravato (esketamine) Nasal Spray for Treatment-Resistant Depression March 5, 2019 -- The U.S. Food and Drug Administration today approved Spravato (esketamine) nasal spray, in conjunction with an oral antidepressant, for the treatment of de

AHA News: Smoking Doubles Stroke Risk Among African-Americans